NeOnc Technologies Holdings, Inc. NTHI 深 滬
已收盤 10-24 16:00:00 美东时间
8.86
+0.510
+6.11%
華盛通- 最 高9.00
- 今 開8.73
- 成交量 2.75万股
- 最 低 8.305
- 昨 收 8.35
- 總市值 1.69亿
- 52周最高 25.00
- 市盈率 靜 --
- 換手率 0.14%
- 52周最低 3.20
- 委 比 93.24%
- 總股本 1902.68万
- 歷史最高 25.00
- 量 比 0.78
- 振 幅 8.32%
- 歷史最低 3.20
- 每 手 1
- 風險率 2.98%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多NeOnc Technologies Announces $50M Partnership with Quazar
An update from NeOnc Technologies Holdings, Inc. ( ($NTHI) ) is now available. ...
10-11 05:34
NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42’s IROS and Expands Board of Directors
NeOnc Technologies Holdings, Inc. has announced two strategic developments: its subsidiary NuroMENA Holdings Ltd. signed a Master Services Agreement (MSA) with Insights Research Organization and Solutions (IROS), a UAE-based CRO part of M42, to leverage advanced healthcare infrastructure for clinical trials, enhancing cancer therapy development. Additionally, NuroMENA's Board of Directors has expanded with key partners from Quazar Investment, rei...
10-09 13:00
NeOnc Technologies and Quazar Investment Set to Close $50 Million Strategic Partnership by October 23rd Following Final UAE Tax Approvals
NeOnc Technologies Holdings, Inc. (NTHI) announced the finalization of its $50 million strategic partnership with Quazar Investment, following the receipt of all necessary tax identification and regulatory approvals from the UAE. The closing is mandated to occur no later than October 23, 2025. The partnership focuses on launching and scaling clinical trials, regulatory filings, and infrastructure development across the UAE and MENA region through...
10-06 13:00
NeOnc Technologies Appoints Dr. David M. Ashley, Director of The Preston Robert Tisch Brain Tumor Center at Duke, to Scientific Advisory Board
NeOnc Technologies Holdings, Inc. has appointed Dr. David M. Ashley to its Scientific Advisory Board. As a leading neuro-oncologist and director of Duke University's Preston Robert Tisch Brain Tumor Center, Dr. Ashley brings extensive expertise in brain tumor immunology and epigenetics to strengthen NeOnc's pipeline, including its Phase II candidates NEO100™ and NEO212™. His leadership and research will guide NeOnc's mission to develop life-chang...
10-02 13:00
NeOnc Technologies Welcomes Dr. Alexandra M. Miller, Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health’s Perlmutter Cancer Center, to Its Scientific Advisory Board
NeOnc Technologies Holdings, Inc. has appointed Dr. Alexandra M. Miller to its scientific advisory board. Dr. Miller, a leading expert in neuro-oncology, is known for her work in liquid biopsy assays for CNS tumors and her expertise in using cerebrospinal fluid for diagnosing and monitoring gliomas. Her insights will support the advancement of NeOnc's clinical trials for NEO100™ and NEO212™. NeOnc is expanding its global trial network, with new s...
10-01 13:00
NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board
NeOnc Technologies Holdings, Inc. (NTHI) has appointed Dr. Henry S. Friedman to its scientific advisory board. Dr. Friedman, a leading neuro-oncologist at Duke University, brings extensive expertise in developing therapies for central nervous system cancers. His加入将进一步推进NeOnc的临床试验项目，包括NEO100™和NEO212™，为脑癌患者带来希望。公司致力于突破血脑屏障挑战，推动创新治疗方案的研发。
09-29 13:00
NeOnc Technologies to Showcase Progress on Addressing Brain Cancer to 63 Million TV Households on “Health Uncensored with Dr. Drew” on the Lifetime Network on September 25, premiering nationwide at 8:00 a.m. ET/PT
NeOnc Technologies Holdings, Inc. will be featured on Health Uncensored with Dr. Drew Pinsky on the Lifetime Network, reaching 63 million households on September 25. Amir Heshmatpour and Dr. Thomas Chen will discuss NeOnc’s platform technology designed to overcome the Blood-Brain Barrier for brain cancer treatment. The company has recently secured a $50 million partnership with Quazar Investment, received FDA authorization for a Phase II trial, a...
09-22 13:00
FDA Authorizes NeOnc Technologies To Proceed With Phase IIa/IIb Of NEO212-01 Clinical Trial
NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced that the
09-10 21:07
Blue Gold Appoints Quazar’s Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy
Blue Gold Limited announced the appointment of Sameer Salgar, Founding Partner and Chief Financial Officer of Quazar Investment, to its Advisory Board. With over 20 years of experience in investment and corporate finance, Salgar will help Blue Gold expand its digital gold platform and strengthen ties with the UAE. Quazar Investment will assist in developing digital technology solutions, establishing gold vault infrastructure in the UAE, and conne...
09-10 13:40
NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer
NeOnc Technologies Holdings, Inc. announced FDA authorization to advance its NEO212-01 clinical trial into Phase IIa/IIb following successful Phase I results. NEO212, a novel oral chemotherapy drug combining Temozolomide with NEO100, aims to overcome limitations of current glioblastoma treatments. The company plans to expand Phase II trials across leading U.S. cancer centers, positioning NEO212 as a potential new standard of care for brain cancer...
09-10 13:00
